Gilead reported 13% third-quarter product sales growth and 3% non-GAAP diluted earnings per share growth. Management increased 2026 product sales guidance by $900 million at the midpoint based on HIV product outperformance and forecast a steeper non-GAAP EPS decline, largely due to acquisitions.
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.63 | 165.74 | 13.48 |
Price/Book Value | 16.25 | 8.80 | 4.00 |
Price/Sales | 6.85 | 5.49 | 2.25 |
Price/Cash Flow | 14.41 | 16.74 | 9.96 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.71 | 0.55 |
Current Ratio | 1.38 | 1.32 | 0.86 |
Interest Coverage | −1.78 | 4.28 | 8.21 |
|
Metric
|
GILD
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.28% | — | 11.16% |
Return on Equity (Normalized) | 39.38% | — | 40.86% |
Return on Invested Capital (Normalized) | 18.09% | — | 21.39% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#cF$#%J | LOCK|?h | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|BFNfQ%g | LOCK|wj | $658B | |||
| AbbVie Inc
ABBV
| LOCK|$Q!cpNx | LOCK|p#> | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|%L!d#HJ$ | LOCK|$!M | $391B | |||
| Merck & Co Inc
MRK
| LOCK|^NHdfh& | LOCK|wr | $369B | |||
| Novartis AG ADR
NVS
| LOCK|?^n#%%<> | LOCK|##F | $307B | |||
| AstraZeneca PLC
AZN
| LOCK|D<X&HMB | LOCK|Z^ | $290B | |||
| Amgen Inc
AMGN
| LOCK|RH^J^t< | LOCK|?&q | $252B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|>s<k$F | LOCK|<%# | $176B |
United States